Darbepoetin Alfa

Epoetin Alfa, Erythropoietin, Novel Erythropoieses Stimulating Protein

Mechanism :

Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signalling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.

Indication :

• Treatment of anemia associated with chronic kidney disease
• Chemotherapy

Contraindications :

Uncontrolled hypertension.

Pure red cell aplasia (PRCA) that begins after treatment.

Serious allergic reactions.

Dosing :

CKD:

Under 1 month: Safety and efficacy not established.

Above 1 month: 50 units/kg IV/SC thrice weekly.

Chemotherapy related:

Under 5 years: Safety and efficacy not recommended.

Above 5 years: 600 units/kg IV once a week: Max: 40,000 units.

Adverse Effect :

Cough, stomach pain, local injection swelling, redness, rash, itching, difficulty breathing or swallowing, wheezing, angioedema, tachycardia, tiredness, lack of energy, dizziness, fainting, pale skin.

Interaction :

None known.

Renal Dose :

Hepatic Dose :